A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer With an Expansion Cohort For Head and Neck Cancer: A Brown University Oncology Research Group Study
Phase of Trial: Phase I/II
Latest Information Update: 03 Aug 2018
Price : $35 *
At a glance
- Drugs Eribulin (Primary) ; Cetuximab
- Indications Colon cancer; Head and neck cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 09 Feb 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 02 Aug 2013 Additional lead centre added as reported by ClinicalTrials.gov.